Loading...
Market
Level of milestone payments achieved by Monte Rosa from Novartis by end of 2025?
2
Resolution / Starting Odds
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Official announcements and financial reports from Monte Rosa Therapeutics or Novartis
Story
Monte Rosa and Novartis Sign $150M Global License Agreement with $2.2B Milestone for Molecular Glue Degraders
Oct 28, 2024, 12:56 PM
Monte Rosa Therapeutics has announced a global license agreement with Novartis to advance T and B cell-modulating VAV1-directed molecular glue degraders. The deal includes a $150 million upfront payment from Novartis, with potential future milestone payments reaching up to $2.2 billion. The agreement aims to develop, manufacture, and commercialize innovative drug candidates, including MRT-6160, which is currently in Phase 1 trials. This partnership is expected to significantly impact the field of immunology and inflammation (I&I) therapeutics. Monte Rosa's CEO Markus Warmuth, Chief Medical Officer Filip Janku, and Chief Data & Information Officer Jocelyn Castle are key figures in this collaboration. Monte Rosa's stock jumped 32.1% pre-market following the announcement, and the deal includes a 30% US P&L share for Monte Rosa.
View original story
Similar markets
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Yes • 50%
No • 50%
Milestone 1 • 25%
Milestone 2 • 25%
Milestone 3 • 25%
No milestone achieved • 25%
Yes • 50%
No • 50%
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
